Last reviewed · How we verify
NCT04968119
Telehealth Exercise Platform to Reduce Frailty After Bone Marrow Transplant
NA trial testing Exercise Intervention in Hematopoietic and Lymphoid Cell Neoplasm in 21 participants. Completed in 8 October 2024.
8 October 2024
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 21 |
| Start date | 12 July 2021 |
| Primary completion | 8 October 2024 |
| Estimated completion | 8 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Exercise Intervention
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Hematopoietic and Lymphoid Cell Neoplasm — all drugs for Hematopoietic and Lymphoid Cell Neoplasm →
Sponsor
City of Hope Medical Center
Who can join
18 and older, any sex, with Hematopoietic and Lymphoid Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial studies the feasibility of implementing a telehealth exercise platform to reduce frailty in patients after bone marrow transplant. The exercise program uses a telehealth platform (e.g. smart phones, tablets or computers) to view pre-recorded exercise videos on coordination, posture, stretching, balance and resistance/aerobic training. Physical activity may help to improve physical function, including frailty, after bone marrow transplant. Information from this trial may help researchers design future telehealth exercise routines for treating people with cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Feasibility of implementing a supervised telehealth exercise intervention in frail survivors of hematopoietic cell transplantation: a pilot randomized trial.
Lee K, Shamunee J, Lindenfeld L, Ross E, et al · · 2023 · cited 16× · PMID 37127595 · DOI 10.1186/s12885-023-10884-5
Verify or expand the search:
- PubMed search for NCT04968119
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exercise Intervention
Trials testing the same drug.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT06565260 — Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors · NA · recruiting
- NCT07302230 — Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Amon · NA · recruiting
- NCT07340281 — Biomarkers for Exercise · NA · recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
Other recruiting trials for Hematopoietic and Lymphoid Cell Neoplasm
Currently open trials in the same condition.
- NCT05711667 — A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patien · Phase 3 · recruiting
- NCT06184321 — Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion · EARLY_PHASE1 · recruiting
- NCT06089408 — Weighted Blanket Use to Reduce Anxiety in Oncology Patients · NA · recruiting
- NCT05663502 — Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers · recruiting
- NCT05178472 — Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) · NA · recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04968119 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 6 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04968119.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing